Abstract 3219
Background
Individuals newly diagnosed with cancer may experience impairments in several aspects of health and often have a high need for both information and support. Approximately 30 % will experience symptoms of anxiety and depression with varying needs of support. E-health interventions such as internet-based interactive health communication applications (IHCAs) may offer a supplement to standard care services. Developers of such interventions need to work closely with presumptive users to add relevance and value. The purpose was to explore the user experiences of an IHCA targeting individuals with breast- colorectal or prostate cancer with symptoms of anxiety and depression.
Methods
A qualitative study with inductive approach was conducted, where 15 individuals using an IHCA targeting symptoms of anxiety and depression were interviewed with semi-structured questions. Content analysis was used to analyze interviews.
Results
The need for information was described as high, and almost looked upon as a survival strategy when newly diagnosed. The IHCA was experienced as a useful, reliable source of information and support, and was used as a complement to standard care. Increased knowledge was a foundation for continued processing of own feelings and the favorable time to get access to the IHCA was when being informed of the diagnose. The common denominator was that of being acknowledged but with a further desire for individual adjustment to own situation and needs.
Conclusions
The IHCA was experienced as a safe and reliable complement to standard care. Similar interventions may gain from a more individualized content, being integrated in to standard care and/or by using tracking of symptoms to adjust the content. Offering the IHCA closer to diagnosis may provide more benefits to users.
Clinical trial identification
NCT-01630681.
Editorial acknowledgement
Legal entity responsible for the study
Regional Committee for Research Ethics Sweden, Uppsala county (Dnr 2012/003/9).
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4370 - Continental differences in pathologic response with neoadjuvant ipilimumab (IPI) plus nivolumab (NIVO) in patients with macroscopic stage III melanoma in the phase 2 OpACIN-neo trial.
Presenter: Irene Reijers
Session: Poster Display session 3
Resources:
Abstract
3230 - Comparable responses of melanoma at primary site and synchronous lymph node metastases upon neoadjuvant ipilimumab (IPI) and nivolumab (NIVO)
Presenter: Judith Versluis
Session: Poster Display session 3
Resources:
Abstract
3171 - Adjuvant Therapies for Stage III Melanoma: Benchmarks for Bringing Clinical Trials to Clinical Practice
Presenter: Tina HIEKEN
Session: Poster Display session 3
Resources:
Abstract
3493 - Mixture-cure modeling for resected stage III/IV melanoma in the phase 3 CheckMate 238 trial
Presenter: Jeffrey Weber
Session: Poster Display session 3
Resources:
Abstract
3036 - An open-label, non-randomized, phase IIIb study of trametinib in combination with dabrafenib for patients with unresectable advanced BRAFV600-mutant melanoma: a subgroup analysis of patients with brain metastasis
Presenter: Caroline Dutriaux
Session: Poster Display session 3
Resources:
Abstract
2233 - Adverse event (AE) kinetics in patients (pts) treated with dabrafenib + trametinib (D + T) in the metastatic and adjuvant setting
Presenter: Jean Jacques Grob
Session: Poster Display session 3
Resources:
Abstract
2435 - A Single Arm, Open Label, Phase II, Multicenter Study to Assess the Detection of the BRAF V600 Mutation on cfDNA from Plasma in Patients with Advanced Melanoma
Presenter: Piotr Rutkowski
Session: Poster Display session 3
Resources:
Abstract
1766 - Efficacy and Safety of Dabrafenib and Trametinib in Patients with Metastatic BRAFV600 Mutation-positive Melanoma in the Real-World Setting – Interim results of the non-interventional COMBI-r study
Presenter: Carola Berking
Session: Poster Display session 3
Resources:
Abstract
2131 - Trial update: A randomized Phase Ib/II study of the selective small molecule Axl inhibitor Bemcentinib (BGB324) in combination with either dabrafenib/trametinib (D/T) or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Poster Display session 3
Resources:
Abstract
4074 - Analysis of pyrexia in patients (pts) treated with dabrafenib (D) and/or trametinib (T) across clinical trials
Presenter: Caroline Robert
Session: Poster Display session 3
Resources:
Abstract